Curated Optogenetic Publication Database

Search precisely and efficiently by using the advantage of the hand-assigned publication tags that allow you to search for papers involving a specific trait, e.g. a particular optogenetic switch or a host organism.

Qr: host:"5637 cells"
Showing 1 - 2 of 2 results
Sort by:
1.

Engineering a 660 nm-Responsive Optogenetic Inducer of Pyroptosis for Precision Cancer Therapy.

blue red BphS Magnets MagRed PhyA/FHY1 5637 cells BIU-87 HEK293T HeLa HK-2 MB49 mouse in vivo mouse neural progenitor cells Neuro-2a T24 Transgene expression Cell death Benchmarking
Adv Sci (Weinh), 31 Jul 2026 DOI: 10.1002/advs.76768 Link to full text
Abstract: Inducing tumor cell pyroptosis represents a promising anticancer strategy; however, uncontrolled pyroptosis not only restricts the production of viral delivery vectors but also poses a risk of systemic damage, thereby limiting the translational application of pyroptosis-based therapies. The development of genetic tools that enable precise spatiotemporal control over pyroptosis remains challenging. To address this, we developed PyroRACS, a bioorthogonal optogenetic inducer for precise pyroptosis induction. PyroRACS utilizes an engineered red-light-activatable Cre-ON genetic switch (RACS) to drive the expression of the gasdermin D N-terminal domain, enabling tunable initiation of pyroptosis without relying on endogenous signaling pathways. We validated robust pyroptosis induction by PyroRACS in multiple cell lines. PyroRACS exhibited high controllability by selectively ablating cancer cells in vitro with precise spatiotemporal resolution. Moreover, its superior controllability enabled the production of the adenovirus vector and allowed "all-in-one" delivery of PyroRACS. In a tumor-bearing mouse model, spatially restricted induction of pyroptosis by PyroRACS resulted in effective tumor suppression, with no detectable systemic toxicity observed under the tested conditions. Collectively, PyroRACS provides a novel optogenetic tool for precise manipulation of pyroptosis, facilitating fundamental research and advancing pyroptosis-based precision oncology therapeutics.
2.

A Light-Inducible Split-dCas9 System for Inhibiting the Progression of Bladder Cancer Cells by Activating p53 and E-cadherin.

blue CRY2/CIB1 5637 cells HEK293T T24 Nucleic acid editing
Front Mol Biosci, 5 Jan 2021 DOI: 10.3389/fmolb.2020.627848 Link to full text
Abstract: Optogenetic systems have been increasingly investigated in the field of biomedicine. Previous studies had found the inhibitory effect of the light-inducible genetic circuits on cancer cell growth. In our study, we applied an AND logic gates to the light-inducible genetic circuits to inhibit the cancer cells more specifically. The circuit would only be activated in the presence of both the human telomerase reverse transcriptase (hTERT) and the human uroplakin II (hUPII) promoter. The activated logic gate led to the expression of the p53 or E-cadherin protein, which could inhibit the biological function of tumor cells. In addition, we split the dCas9 protein to reduce the size of the synthetic circuit compared to the full-length dCas9. This light-inducible system provides a potential therapeutic strategy for future bladder cancer.
Submit a new publication to our database